MRI: The examination lasts between 45 minutes and one hour. The patient lies down in the MRI tube. He is fitted with headphones that muffle the noise produced by the machine and enable him to receive instructions from the technician. Four electrodes are applied to his chest to continuously record his heartbeat. Finally, his chest is covered with a plastic plate, which receives the MRI signals needed to form the image. Acquiring an MRI image takes between 2 and 20 seconds. To ensure that image quality is not impaired by respiratory movements, images are acquired in apnea. The technician will ask the patient to hold his or her breath repeatedly throughout the examination. These apneas must last less than 15 seconds.
Blood sampling: Additional blood will be drawn for dosing acylcarnitines, copeptin, interleukin-6 (IL-6), LPS-Binding Protein (LBP), Phospholipid TransferProtein (PLTP)/Cholesteryl Ester Tranfer Protein (CETP) activity, and for plasma banking. The volume of blood will be 20 ml in total (5 ml for each assay) at each visit. Patients participating in this study will have 3 visits. Total blood volume will therefore be 20 x 3, or 60 ml for the 3 visits.
Study summary
The aim of this multicenter prospective interventional pilot study is to describe the evolution of myocardial fibrosis in cirrhotic patients before and after liver transplantation (LT). Through multimodal analysis of myocardial function and architecture, and analysis of specific markers of inflammation, we aim to explore the following hypotheses: 1) systemic inflammation promotes myocardial fibrosis in cirrhotic patients and could be an early marker of cirrhotic cardiomyopathy; 2) LT allows resolution of myocardial fibrosis by preventing the bacterial translocation that favors the development of deleterious systemic inflammation.
Eligibility
Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
* Inclusion of cirrhotic patients who are candidates for liver transplantation and without documented contraindications to transplantation
* Women who have been menopausal for at least 24 months, surgically sterilized, or, for women of childbearing age, use an effective method of contraception (oral contraceptives, contraceptive injections, intrauterine devices, double-barrier method, contraceptive patches)
* Signature of an informed consent form indicating that the subject has understood the purpose and procedures required by the study and that he or she agrees to participate in the study and to comply with the requirements and restrictions inherent in the study
* Patient with a social security system or beneficiary of such a system.
Exclusion Criteria:
* Minor or over 70 years old
* Transplant Patient
* Patient with a TIPS
* Known heart disease including portopulmonary hypertension and coronary artery disease (history of ischemic heart disease with necrosis, history of cardiomyopathy or acute myocarditis)
* Uncontrolled hypertension with interventricular septal thickness ≥ 15 mm
* Hemodynamic instability
* Type 1 diabetes
* Current bacterial infection
* HIV infection (or unknown HIV status)
* Contraindications for MRI including pacemaker, implantable defibrillators, electrosystolic pacing probe, Swan-Ganz probe, postoperative epicardial electrodes, Starr-Ewards metal ball valves, insulin pumps, ferromagnetic vascular clips, ocular and otological implants, ocular ferromagnetic foreign bodies, renal failure with a GFR \< 30 mL/min/1.73 m², contraindication to contrast media, patient unable to maintain apnea for a few seconds, claustrophobia
* Inability to receive informed information in patients with severe encephalopathy who do not have a trusted person
* Patient under guardianship, curatorship, Legal incapacity or limited legal capacity
* Patient deprived of liberty
* Pregnant woman or breastfeeding
* Subject unlikely to cooperate in the study and/or low cooperation anticipated by the investigator
* Subject being in the period of exclusion from another study or provided for by the "national volunteer file"
Primary outcome measure(s)
Primary outcome measure — sixth month-21th month after inclusion Difference in myocardial extracellular volume (MECV) on cardiac MRI between the pre-LT visit (visit 2) and 12 months after LT (visit 3). If patients are transplanted less than 6 months after the inclusion visit, visit 2 will not be performed and the reference visit will be visit 1.
Trial sites (4)
Facility
City
Region
Status
CHU Besancon - Hopital Minjoz
Besançon
France
Recruiting
CHU Dijon - Hopital François Mitterrand
Dijon
France
Recruiting
CHRU Nancy - Hôpital de Brabois
Nancy
France
Recruiting
CHU Strasbourg - Hopital de HautePierre
Strasbourg
France
Not Yet Recruiting
More Centre Hospitalier Universitaire de Besancon trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
